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Abstract 
Background: Needle-syringe programs (NSP) have been running in Iran since 2002. However, the coverage 
of such program among the NSP clients at the individual level was not studies yet. This study aimed to 
determine the client coverage of NSP and its correlation with high injection-related risk behaviors. 
Methods: A cross-sectional survey was conducted in Kermanshah province, Iran, in 2014. 230 people who 
inject drugs (PWID) recruited from two drop-in centers (DICs) from April to September 2014, participated in 
a face-to-face interview to provide information related individual coverage of NSP, demographic 
characteristics, and injecting behaviors 30 days prior to the interview. 
Findings: Overall, the average of syringe coverage was 158% [95% confidence interval (CI) = 65.7-205.5], 
while 56% (95% CI = 40-97) have individual converge less than 100%. Needle/syringe sharing was 
significantly higher among individual with low NSP coverage [adjusted odds ratio (AOR) = 2.6, 95%  
CI = 1.3-6.2]. About 85% participants with coverage of less than 100% reported reuse of syringe within the 
last 30 days (AOR = 3.2, 95% CI = 1.4-7.7). 
Conclusion: PWID are different regarding their NSP individual-level converges. There are certain clusters of 
PWID, who do not receive sufficient number of syringes. Given that insufficient individual syringe coverage 
level is highly associated with injection risk behaviors, reasons for such low converge need to be assessed and 
addressed carefully. 
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Introduction 
Drug injection is responsible for a huge burden of 
blood-borne transmitted diseases in both 
developed and developing countries.1 It is still a 
challenge for many countries, and in some 
regions, such as Eastern Europe, it is worsening. It 
is estimated that about 12.7 million people inject 
drugs globally, and 1.7 million of those are living 
with human immunodeficiency virus (HIV) 
(13%).2 
Unsafe injection, like needle and syringe 
sharing, is being considered as one of the main 
routes of HIV and other blood-borne diseases 
transmission.3,4 In Iran, it is estimated that  
170000-230000 people inject drugs.5 Moreover, 
68.0% of new HIV infection is attributed to unsafe 
injection.6-8 The HIV prevalence was estimated as 
15.2% in injecting drug users.9 In addition, 
unprotected sexual contacts were reported 
relatively common in this population.9-11 This 
pattern allows the HIV infection spread among 
both injection and sexual networks. Recent study 
of female partners of people who inject drugs 
(PWID) reported HIV prevalence as high as 2.8% 
in such groups.12 
To reduce the risk of transmission and the 
harms associated with injection, harm reduction 
programs have been developed and implemented 
in many countries and different settings.3 
Worldwide, one of the main components of harm 
reduction programs for PWID is needle-syringe 
program (NSP) and/or needle exchange program. 
This program has been developed to prevent 
needle sharing and therefore transmission of HIV 
and other blood borne viruses infections.13 In Iran, 
NSP has been implemented since the beginning of 
the HIV epidemic. The program is delivered 
through drop-in centers (DICs) to those who have 
access to services and by outreach teams to those 
having difficulty in getting access to such 
services.7,14 
Per current national guideline, DICs provide 
sterile needles and syringes services, deliver 
training psychoeducation on safer injecting 
practices and overdose prevention. They also 
provide condom and safe sex training materials 
and consultation. The clients are encouraged to 
regularly visit the sites. The routine service 
includes delivery of a safe injection kit  
(3-4 syringes, 3-4 extra needles, pure water vials, 
and alcohol pads) for everybody self-reported as 
injecting drug user. Such services also offered off 
site by outreach. However, The DICs’ staff 
distribute syringes on the clients’ request during 
every visit to the center or contact with outreach 
workers.6 
Although such harm reduction programs 
contribute to stabilizing the HIV epidemic among 
PWID in Iran, unsafe injection and particularly 
needle/syringe sharing (12.6%) are still being 
reported by injecting drug users.9 
NSP has been implemented in Iran for more than 
a decade, but the client-level coverage of such 
program was not assessed systematically yet. This 
study is to determine the client-level coverage of 
NSP overall and in clusters of people, who inject 
drugs. We also assess whether such coverage 
correlates with any unsafe drug injection behaviors. 
Methods 
This cross-sectional study was conducted in 
Kermanshah, a city of over 850000 people located 
in western part of Iran. The HIV epidemic in Iran 
first observed in Kermanshah in 1996 where the 
most affected people were those who were 
injecting drugs. Since then many services 
implemented in the city, including the NSPs, but 
still it has one of the highest % of HIV in 
population of drug users in Iran. It is epidemic is 
under the radar of National Health Program as 
one of the sentinel sites for monitoring HIV trend 
and response, and so we choose Kermanshah as 
our study site. 
Eligible participants were recruited into the 
study from April to September 2014 after 
providing written informed consent. We recruited 
study participants from two DICs and their 
affiliated outreach sites using convenience 
sampling. Given α = 5%, β = 20%, estimated 
prevalence of sharing injection among PWID as 
10% and the response rate of 10%, we calculated 
the minimum sample size as 230 people. The two 
DICs were located at the central part of the city. 
Both were established since 2004 and so far 
provided sterile needle and syringe services, 
condom and consultation on blood-borne 
diseases, like HIV, hepatitis C virus (HCV) and 
ways on how to reduce the risk of injection. 
Male clients who were 18 years old or more, 
reported drug injection within the last month 
prior to the interview, and mentioned DIC as their 
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main source of syringes in the last 3 months prior 
to the interview and written consented to 
participate in the study were considered as 
eligible and were recruited into the study. The 
study protocol and all the procedures were 
reviewed and approved by the Ethical Committee 
of the Kerman University of Medical Sciences, 
Iran (Ethical code k/93/204). 
At each DIC, a trained male psychologist 
introduced the study objectives, explained the risk 
and benefits of participation in the study as well 
as assessing the eligibility criteria. Then, the 
psychologist interviewed each consented 
individual using a standardized structured 
questionnaire. The questionnaire consisted of five 
sections including demographic information, 
major type of drug, duration of addiction and 
drug injection, rate of injections and drug-related 
risk behaviors such as reuse, sharing (borrowing 
or lending) syringes, needles or cooker 
(paraphernalia which includes bottle caps, 
spoons, or other containers to dissolve drugs into 
water and to heat drugs solutions). To reduce 
recall bias, we used both self-report and program-
registered data to identify the number of sterile 
syringes provided by DIC over the month prior to 
the interview. Self-reported injecting frequency 
was estimated from the number of days injected in 
the previous month multiplied by approximate 
number of times injected per day. To prevent from 
introducing sampling bias, we did not incentivized 
participants. Anyway, they have been receiving 
routine services provided in the DIC. 
The content validity of the questionnaire was 
assessed and approved by eight experts in the 
field of behavioral surveys, epidemiology, and 
harm reductions. Over time reliability of the 
questionnaire was assessed by interviewing 10 
eligible people twice with a two-week interval. 
The overall intra-class correlation estimated as 
0.87 indicating acceptable range of reliability. 
To calculate the client-level syringe coverage, 
we used the Bluthenthal et al. formula.15 The 
formula evaluates the ratio of sterile syringe 
received per injection. For example, a person 
which 20 injections per month, who received 10 
sterile syringes from the DIC during the month 
prior to the interview, will have a coverage of 
10/20 × 100 = 50%. Based on the client-level 
coverage, participants were divided into two 
groups; those with the coverage less than 100% 
(low coverage) and those with coverage of 100% 
or more (sufficient coverage). We estimated the 
prevalence of coverage overall and among 
different subgroups. Furthermore correlation 
between drug-related risk behaviors, self-reported 
blood born infections (e.g. HCV and HIV) and 
syringes low coverage was assessed by  
Chi-square test or fisher exact test. Variable with 
significant P < 0.200 in the crude analysis, after 
checked of collinearity, were included in the 
multiple logistic regression models. P < 0.050 was 
considered as statistically significant. The 
correlations of predictors with the outcome were 
reported as adjusted odds ratio (AOR) point and 
confidence interval (CI) 95%. All data analysis 
was performed using Stata software (Version 11, 
Stata Corp, College Station, Texas). 
Results 
A total of 230 men who injected drugs 
participated in this study. The mean age ± 
standard deviation (SD) was 34.5 ± 8.6 (range  
19-58) years. The majority (41%) of respondents 
had guidance school education. 11% of 
respondents were married, and the majority 
reported as being single (56%). The majority of 
participants were unemployed (64%), had a 
monthly income less than $150 (86%), and 
homeless (43%). 
While 38% of study subjects did not know 
their HCV status, 22% reported as HCV positive. 
Regarding HIV status, 10% did not know their 
serostatus and 14% reported as positive. Heroin 
was reported as the most common used drug 
(70%), followed by methamphetamine (29%). The 
mean age at first drug use was 21.3 ± 11.6 years 
old, and mean age at first drug injection was  
27.3 ± 13.8 years old (Table 1). 
Client-level coverage of NSP 
Overall, the average of syringe coverage was 158% 
(95% CI = 65.7-205.5) and the median of syringe 
coverage was 93%. Overall, 56% (95% CI = 40-97) of 
participants had coverage less than 100%. 
The client-level of NSP coverage among 
different subgroups reported in table 2. 
Surprisingly, 66-67% of PWID aged between 30 
and 50 years had coverage less than 100%, 
significantly higher than younger and older ones. 
Regarding education, the lowest coverage was 
observed among people who were either illiterate 
(60%) or had academic education (67%)  
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(P = 0.300). 78% of those with a fulltime job had 
NSP coverage more than 100% (P = 0.070). About 
50% of people with stable housing status reported 
coverage less than 100% (P = 0.100). 
 
Table 1. Demographic and drug related characteristics of people who inject drug (PWID) 
(n = 230) 
Characteristics n (%) 
Age (year)   
< 30 84 (37) 
30-39 78 (34) 
40-49 51 (23) 
≥ 50 13 (6) 
Education   
Never attended school or elementary 53 (23) 
Guidance school 94 (41) 
High school 77 (33) 
University 6 (3) 
Marital status   
Single 131 (56) 
Married 22 (11) 
Divorced 43 (19) 
Widowed 4 (2) 
Married but living alone 30 (12) 
Occupation   
Full time 18 (6) 
Regular part- ime 12 (5) 
Irregular part-time 47 (20) 
Student 7 (5) 
Unemployed 146 (64) 
Monthly income ($)   
< 150 200 (86) 
≥ 150 30 (14) 
Living place   
Home 124 (55) 
Camp 5 (2) 
Homeless 100 (43) 
Self-reported HCV status   
Negative 91 (40) 
Positive 50 (22) 
Unknown 90 (38) 
Self-reported HIV status   
Negative 175 (76) 
Positive 32 (14) 
Unknown 23 (10) 
Current most frequent drug   
Heroin 161 (70) 
Methamphetamine 67 (29) 
Other 2 (1) 
Age at first drug use (year)   
< 25 200 (88) 
25-29 22 (10) 
≥ 30 8 (2) 
Age at first drug injection   
< 25 138 (60) 
25-29 46 (20) 
≥ 30 46 (20) 
HCV: Hepatitis C virus; HIV: Human immunodeficiency virus 
 
Coverage of Needle and Syringe Program and High-Risk Injection Noroozi et al. 
 
 
168 Addict Health, Summer & Autumn 2015; Vol 7, No 3-4 
 
http://ahj.kmu.ac.ir,    7 October 
Table 2. Bivariate analysis of client-level syringe coverage in different subgroups of people who 
inject drug (PWID) (n = 230) 
Characteristics 
Client-level syringe coverage* 
P < %100 ≥ %100 
n (%) n (%) 
Age (year)    
< 30 35 (41) 51 (59) 
0.005 
30-39 53 (66) 27 (34) 
40-49 34 (67) 17 (33) 
≥ 50 6 (46) 7 (54) 
Education    
Never attended school or elementary 32 (60) 22 (40) 
0.300 
Guidance school 52 (56) 41 (44) 
High school 40 (52) 37 (48) 
University 4 (67) 2 (33) 
Marital status    
Single 62 (48) 67 (52) 
0.100 
Married 15 (65) 8 (35) 
Divorced 32 (73) 12 (27) 
Widowed 3 (51) 2 (49) 
Married but living alone 16 (55) 13 (45) 
Occupation    
Full time 3 (22) 11 (78) 
0.070 
Regular part-time 6 (60) 4 (40) 
Irregular part-time 31 (64) 17 (36) 
student 7 (57) 3 (43) 
Unemployed 87 (59) 62 (41) 
Monthly income ($)    
< 150 104 (56) 80 (40) 
0.500 ≥ 150 24 (52) 22 (48) 
Living place    
Home 63 (50) 63 (50) 
0.100 Camp 3 (60) 2 (40) 
Homeless 62 (62) 38 (38) 
Current self-reported HCV status    
Negative 45 (51) 44 (49) 
0.600 Positive 31 (62) 19 (38) 
Unknown 51 (57) 39 (43) 
Current self-reported HIV status    
Negative 97 (55) 78 (45) 
0.500 Positive 15 (50) 15 (50) 
Unknown 16 (63) 9 (37) 
Current most frequent drug    
Heroin 92 (58) 68 (42) 
0.400 
Methamphetamine 36 (51) 34 (49) 
Age at first drug use (year)    
< 25 116 (58) 85 (42) 
0.100 25-29 10 (47) 11 (53) 
≥ 30 2 (25) 6 (75) 
Age at first drug injection    
< 25 77 (55) 62 (45) 
0.300 25-29 30 (65) 16 (35) 
≥ 30 21 (47) 24 (53) 
*The ratio of the number of syringes received from needle-syringe exchange program divided by the 
number of client’s self-reported injections. 
HCV: Hepatitis C virus; HIV: Human immunodeficiency virus 
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Table 3. Bivariate analysis of reuse, sharing needle/syringes and cookers by client-level syringe coverage, people who 
inject drug (PWID) (n = 230) 
Characteristics 
Client-level syringe coverage* 
P < %100 ≥ %100 
(n = 129) (n = 101) 
Behaviors n (%) (95% CI) n (%) (95% CI)  
Syringe reuse within past month      
Yes 114 (86) (73.8-87.4) 67 (67) (57.1-75.6) 
0.001 
No 15 (14) (6.1-7.2) 34 (33) (24.4-44.9) 
Receptive syringe sharing within past month      
Yes 20 (15) (9.3-21.7) 6 (6) (1.3-10.8) 
0.020 
No 109 (85) (78.3-90.7) 95 (94) (89.4-98.7) 
Distributive syringe sharing within past month      
Yes 13 (11) (4.9-15.3) 11 (11) (4.8-17.2) 
0.100 
No 116 (89) (84.7-95.1) 90 (89) (83.2-95.2) 
Shared cookers within past month      
Yes 88 (70) (60.2-76.3) 36 (36) (26.3-45.1) 
0.001 
No 41 (30) (23.7-39.8) 65 (64) (55.2-73.2) 
*The ratio of the number of syringes received from needle-syringe exchange program divided by the number of client’s self-reported 
injections. 
CI: Confidence interval 
 
Table 4. Crude and adjusted odds ratio for low client coverage and different high-risk behavior outcomes 
*Client-level 
syringe coverage  
< %100 
Drug-related high-risk behavior outcome 
Syringe reuse within 
past month 
Receptive syringe 
sharing within past 
month 
Distributive syringe 
sharing (lend) within 
past month 
Shared cookers within 
past month 
OR AOR OR AOR OR AOR OR AOR 
















No 1 1 1 1 1 1 1 1 
*The ratio of the number of syringes received from needle-syringe exchange program divided by the number of client’s self-reported 
injections. OR and AOR were adjusted for all covariates with P < 0.200 in univariate analysis which included age, age at first drug 
use, marital status, occupation, and living status.  
OR: Odds ratio; AOR: Adjusted odds ratio 
 
The majority of HCV positive cases had low 
coverage (62%) (P = 0.600), and only 50% of  
HIV-positive cases reported sufficient coverage  
(P = 0.500). The type of drug people injected had 
no statistically relationship with NSP coverage  
(P = 0.400). Those who started using drug after 30 
years old had reported the lowest coverage (25%). 
The majority (65%) of people who started 
injection between 25 and 30 years old were under 
coverage of 100%. 
NSP client-level coverage and injection-related 
high-risk behaviors 
As reported in table 3, 86% of participants with 
low coverage reported syringe reuse within past 
month prior to the interview, significantly higher 
than those with > 100% NSP coverage. Receptive 
syringe sharing (15 vs. 6%) and shared cooker (70 
vs. 36%) was also reported significantly more 
among those with low coverage. 
In table 4, the crude and AOR for low client 
coverage (coverage < 100%) and different high-risk 
behavior outcomes reported. The odds of syringe 
reuse among people with insufficient NSP coverage 
(coverage < 100%) was 3.5 times the odds of people 
with sufficient coverage. It reduced to 3.2 when 
adjusted for other covariates, but still remained 
statistically significant. The AOR for other outcomes 
like receptive syringe sharing (AOR = 2.6) and 
shared cooker (AOR = 3.2) was also significant. 
Distributive syringe sharing was higher (AOR = 1.4) 




This study was conducted to examine the client-
level coverage of NSP and its correlation with 
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unsafe drug injection behaviors among PWID. 
While the average of NSP individual coverage 
was high as 158%, only half of injecting drug 
users who are linked to NSP program either 
directly or through outreach, being provided 
sufficient syringes (coverage > 100%). Bluthenthal 
et al. in their study of injectors in California 
reported that 47% of the individuals referring 
program had coverage of above 100% and the 
mean individual coverage was estimated 365%.15  
In another study in Australia, the average of 
individual coverage average was reported as 
320%.16 Such reported estimates were significantly 
higher than what we observed in our study. No 
study has examined program’s individual- 
coverage to date in Iran and therefore the findings 
on coverage could not be satisfactorily compared 
over time; however, program coverage was 
calculated in 2013 on base geographic index.17 
This index is estimated based on the number of 
distributed syringes and the number of injecting 
drug users in community.18 Using such index, 
program coverage was 55-77 syringes per 
injecting drug user, representing increased 
coverage of the program in comparison to the 
past and injecting drug users’ high access to 
sterile syringe and needle. Although it is much 
less than desirable status (200 syringes per 
injecting drug user).17 
We found that some clusters of PWID have 
been receiving less number of syringes relative to 
their injection frequency than others. PWID at 
middle age (30-50 years), with unstable 
employment and housing status, and who started 
drug use later reported lower coverage. This 
finding is in line with other studies.15,19 Unstable 
employment and housing have reported as 
predictors for low self-esteem and also poor 
health care.20,21 We also observed that they might 
also lead to low access and use of NSP services. 
We found that as syringe coverage percentage 
increased, the odds of syringe re-use and 
injection-related HIV risk decreased significantly. 
In our study, PWID with syringe coverage of 
100% or more were significantly less likely to 
reuse their own syringes, share syringes and 
cookers than those with coverage lower of 100%. 
It also reported in the literature that about 9% of 
people with sufficient coverage of NSP still 
sharing needles, which is comparable to our 
findings (7%).15 
Similar to our findings, Bluthenthal et al.22 
found that syringe reuse is less frequent in the 
individuals with 100% coverage and above than 
those with lower coverage. Although syringe 
reuse does not contribute to transmitting  
blood-borne diseases, it could greatly contribute 
to skin and cellulite infections.23 Syringe reuse 
could in turn be a proxy for program’s individual 
coverage.22  
High access and so individual coverage have 
been shown to contribute greatly in decreasing 
syringe and needle sharing rates.6,15,22,24,25 
Together these results suggest that achieving 
100% syringe coverage is important, and the 
amount of syringes that PWID receive at NSP 
should correspond to the individual frequency of 
injection.15,24 Another interesting finding was that 
when PWID do not share syringes, they also less 
likely to share cookers, which has been reported 
more common than syringe/needle sharing by 
drug injectors.26  
We did not directly measure the cooker 
individual-converge to be able to assess its 
predictors. This association might not be casual, 
existing of instrumental variables or common 
causes of both syringe and cooker sharing, or 
clustering in time, but could be this association 
is important from the view of health policy 
makers, that increasing the amount of syringe 
distribution will decrease the chance of cooker 
sharing as well. We observed that the likelihood 
of lending syringes do no increase by increasing 
the coverage of syringes. This, in fact, could be 
explained as herd immunity phenomena,27 
when every drug injectors in a community have 
been given plenty of syringes (through NSPs), 
then nobody need to ask for borrowing one 
from another injector, and so the overall chance 
of syringe lending would be decreased. We 
should acknowledge the limitation of our study. 
Like any cross-sectional studies, we can only 
report the association of low coverage with 
high-risk behaviors. Although, our observation 
was strong, consistent for different risk-
behaviors, stable and precise after adjusting for 
covariates and in line with theory and other 
evidences, we think the causal inferences 
should be done in experimental or observation 
longitudinal studies. We acknowledge that our 
results are not generalizable to PWID who do 
not attend NSPs. Furthermore; our data were 
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based on participants self-report and therefore 
may be subject to recall bias and social 
desirability bias.28  
Biomarker studies and sequencing of HCV and 
HIV infection could be a way to overcome  
self-reporting biases.29 We observed wide CIs, 
which was due to lack of overlap between the two 
groups (sufficient vs. insufficient converge) over 
the strata of the all covariates in each high-risk 
behavior analysis. 
Conclusion 
We observed an insufficient coverage of NSP in 
PWID. To prevent from further transmission of 
HIV and HCV infection, number of 
needle/syringes provided need to be corresponds 
to the frequency of drug injection for each client. 
This could be done by encouraging more frequent 
visits, increasing hours and locations, and 
providing more syringes per visit. 
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